UK markets open in 6 hours 28 minutes

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
105.82-0.21 (-0.20%)
At close: 04:00PM EDT
105.32 -0.50 (-0.47%)
After hours: 07:25PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • W
    GERN is the next NVO
  • E
    Nvo pretty good value Under 100
  • B
    One of my favorite stocks, wish I had more LOL
  • D
    i cant find anything bad in this ER. what did i miss?
  • B
    CagriSema another once-weekly that might go oral as semaglutide did. If so with CagriSema weight loss figures Share Price might get "obese" but in a good way of saying that make all feel better. Also look at oral fdc sema/SGLT2i clinical study on initiation dosage now Phase 2 according to latest IP. Oral semaglutide label obesity in phase 3. To make a vulcano of SP SNAC might be useful to oralize once weekly Icodec and somapacitan as EMISPHERE (originator of SNAC bought by NVO) failed with insulin and growth hormone using H1/2 < 6 hours version, with once weekly version (as semaglutide) SNAC could be in the race for oral insulin and hGH.
  • J
    Since the share price drop seems to be a mystery to everyone, let me spell it out: Q4 sales were 38.3B DKK, Q1 Sales were 42B, Q2 sales were 41.3B (i.e. -0.7B vs Q2). Share price dropped because sales shrunk vs. Q1. NVO did raise full year guidance, but I think the market knew the guidance was conservative to begin with, and thus had much higher expectations.
  • C
    What is the dividend for the ADR in $US dollars ??
  • J
    John Smith
    Ozempic sales are going to go ballistic over the next few years. Shortages in the U.S, Israel and Australia. Stock a bit overpriced rn IMO, but will be a great long term hold.
  • h
    NVO was just 110 AH yp $3.25. now up .40 cents

    Look out Monday here comes $110 plus
  • l
    NVO is having trouble keeping up with demand for the diabetic community due to doctors prescribing for weight loss. Australia and Israel for example. And it's just the beginning for the weight loss market.
  • F
    I have been holding 400 shares since the 2018. This dip was too hard to resist. Bought another 100 shares at the close. The numbers look too good to pass up!
  • D
    once Wegovy in pill form make it Over the Counter at 50 bucks a month. Half the USA population would be on it. That would easily be more than a billion a month. At 50 a month only need 20 million people.
  • B
    Where are current comments concerning NVO & its sales growth for Ozempic & Wegovy?
  • E
    Strong us dollar helps this company!!!
  • J
    It appears that the stock is lower because of the slight reduction in Revs from Q1 to Q2. But historically this has been the case (in both 2021 and 2020, sales decreased from Q1 to Q2 then took off the rest of the year). And they are projecting increases (in fact adjusting up) the remainder of 2022 as well. My question is why sales (historically) drop in Q2 vs Q1? Is there a good reason?
  • L
    Sold over half my holding a while back - great company but I think the market expectation has got well ahead of itself. This stock is still trading on a P/E of 35 almost double what it was a couple of years back when it had just about 12% less income.
    I suspect this will drift below $90 at some point, but on my remaining holding I think it's for the long term so won't abandon any more of my holding.
  • F
    Looks like all the shorts are still asleep....
  • L
    relationship maintained 3 Straight days. not a fluke. rip shorts , its started
  • s
    Does novo sneak in and buy MDGL for the First! approved nash drug
  • W
    $237 BB CAP, am sure debts are a horror